A Phase 4 interventional study of Definity in Pulmonary Heart Disease, sponsored by Lantheus Medical Imaging. Completed at 8 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-11-24.
Sponsored by Lantheus Medical Imaging (part of Lantheus Holdings, Inc.) · Phase 4, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies in Pulmonary Heart Disease with a site in United States — 1 open to participants now, 1 under way, none of them phase 3. Pulmonary Heart Disease · United States.
Among the 19 studies in Pulmonary Heart Disease with a site in United States, this one is the 7th largest by enrollment of the 11 interventional ones that give a count, is one of 2 that started in 2009, is one of 2 in phase 4, and was the 3rd registered.
42 studies on the registry are indexed under Pulmonary Heart Disease; 6 are open to participants now.
Browse Pulmonary Heart Disease studies →1 of the 19 studies in Pulmonary Heart Disease with a site in United States is open now. Recruiting first, the newest first:
Baystate Medical Center · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 2 Pulmonary Heart Disease studies recruiting now, 1 sets no upper age limit and none stop at 75 or younger; none take children under 18; none take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
First in 1999; this study’s year is marked. 2 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 32 is below the median of 50 across 23 interventional studies indexed under Pulmonary Heart Disease.
Median enrollment 41 across the 11 interventional studies, 60 across the 7 observational. Of the 16 that completed or were terminated, 4 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 19 have an industry lead sponsor. The 10 most frequent:
This study is registered under Lantheus Medical Imaging, one of the names counted as Lantheus Holdings, Inc.. Under that name alone:
Lantheus Medical Imaging is the lead sponsor of 30 studies on the registry; 3 are open to participants now.
Lantheus Holdings, Inc. has 1 study filed under Pulmonary Heart Disease — fewer than ten, so there is no comparison to draw.
1 of the studies in Pulmonary Heart Disease with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05733767Baystate Medical CenterSmoking Cessation Pharmacotherapy-Nurse Practitioner Led Tobacco Treatment Team Study | 2027-08-28 |
Add it to your calendar (.ics) → With an account.
Among the 19 studies in Pulmonary Heart Disease with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this clinical research is to learn if DEFINITY® 416 will cause any adverse effects during Right Heart Catheterization. This research was requested by the FDA.
This Phase IV safety study will provide safety data on potential systemic and pulmonary hemodynamic effects caused by the administration of DEFINITY® in patients who are to undergo right heart cardiac catheterization for clinical reasons. Using a right heart catheter for direct measurements of pulmonary artery hemodynamics will allow accurate assessments of potential alterations of the pulmonary vasculature. This will be further investigated by the inclusion of two patient populations, one with a baseline pulmonary artery pressure \< 35 mmHg, and one with elevated baseline pulmonary artery pressure. The addition of immune parameter measurements will assess a potential link between systemic and pulmonary alterations and potential immune reactions following DEFINITY® administration.
The inclusion of patients in this study is not based on a required echocardiogram with DEFINITY® administration because patients would be exposed to an unjustifiable risk of invasive right heart catheterization and are unlikely to consent to such a procedure. Therefore, patients undergoing heart catheterization for clinical reasons, or patients who are undergoing pulmonary artery hemodynamic assessments will be enrolled and receive DEFINITY® in this study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Women of Child-Bearing Potential(WOCBP) who:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects with pulmonary arterial pressure (PAP) of \< or = to 35 mmHg.
Drug: Definity
Subjects with a PAP of \> or = to 35 mmHg.
Drug: Definity
one bolus dose of Definity per intravenous injection, 30-60 second injection, dose value calculation = maximum of 10 microliter/kg patient weight
Also known as: Perflutren Lipid Microsphere
Percent Change in Pulmonary Artery Pressure Change From 1 Minute Pre-dose to 31 - 35 Minutes Post Dose
Percent change in pulmonary atery pressure change from immediately pre-dose to 31 - 35 minutes post dose
Time frame: 31-35 minutes minus baseline
Immunology Panel- Complement 3A (C3A)
Evaluate the Immunology Panel after the administration of DEFINITY
Time frame: Out to 70 minutes
Immunology Panel- Complement 5A(C5A)
Evaluate the Immunology Panel after the administration of DEFINITY
Time frame: Out to 70 minutes
Immunology Panel- Interleuken-6
Evaluate the Immunology Panel after the administration of DEFINITY
Time frame: Out to 70 minutes
Immunology Panel- Tryptase
Evaluate the Immunology Panel after the administration of DEFINITY
Time frame: Out to 70 minutes
participants were recruited from hospitals and clinics in the USA between July 2009 and December 2009
| Milestone | Low Pulmonary Arterial Pressure | Elevated Pulmonary Arterial Pressure |
|---|---|---|
| Started | 16 | 16 |
| Completed | 16 | 16 |
| Not completed | 0 | 0 |
Percent change in pulmonary atery pressure change from immediately pre-dose to 31 - 35 minutes post dose
| mm Hg | Low Pulmonary Arterial Pressure | Elevated Pulmonary Arterial Pressure |
|---|---|---|
| Percent Change in Pulmonary Artery Pressure Change From 1 Minute Pre-dose to 31 - 35 Minutes Post Dose | -1.9 ± 18.03 | -1.7 ± 10.25 |
Evaluate the Immunology Panel after the administration of DEFINITY
| ng/ml | Low Pulmonary Arterial Pressure | Elevated Pulmonary Arterial Pressure |
|---|---|---|
| Immunology Panel- Complement 3A (C3A) | -45.80 ± 338.14 | -38.20 ± 414.86 |
Evaluate the Immunology Panel after the administration of DEFINITY
| ng/ml | Low Pulmonary Arterial Pressure | Elevated Pulmonary Arterial Pressure |
|---|---|---|
| Immunology Panel- Complement 5A(C5A) | -0.95 ± 3.56 | 0.78 ± 4.55 |
Evaluate the Immunology Panel after the administration of DEFINITY
| pg/ml | Low Pulmonary Arterial Pressure | Elevated Pulmonary Arterial Pressure |
|---|---|---|
| Immunology Panel- Interleuken-6 | 0.31 ± 1.46 | 0.15 ± 2.11 |
Evaluate the Immunology Panel after the administration of DEFINITY
| ug/ml | Low Pulmonary Arterial Pressure | Elevated Pulmonary Arterial Pressure |
|---|---|---|
| Immunology Panel- Tryptase | -0.24 ± 0.82 | -0.01 ± 1.46 |
Collected over Through 32 hours. Non-serious events are listed at a 0.5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Low Pulmonary Arterial Pressure | — | 0/16 (0%) | 4/16 (25%) |
| Elevated Pulmonary Arterial Pressure | — | 0/16 (0%) | 5/16 (31.3%) |
| Event | Low Pulmonary Arterial Pressure | Elevated Pulmonary Arterial Pressure |
|---|---|---|
| MyalgiaMusculoskeletal and connective tissue disorders | 2/16 | 3/16 |
| Chest PainGeneral disorders | 0/16 | 1/16 |
| Back PainMusculoskeletal and connective tissue disorders | 1/16 | 1/16 |
| Neck PainMusculoskeletal and connective tissue disorders | 0/16 | 1/16 |
| DizzinessNervous system disorders | 1/16 | 0/16 |
| HeadacheNervous system disorders | 1/16 | 0/16 |
| Age, Continuous(years) | Low Pulmonary Arterial Pressure | Elevated Pulmonary Arterial Pressure | Total |
|---|---|---|---|
| Mean | 56.9 ± 10.8 | 57.4 ± 15.1 | 57.2 ± 12.9 |
| Sex: Female, Male(Participants) | Low Pulmonary Arterial Pressure | Elevated Pulmonary Arterial Pressure | Total |
|---|---|---|---|
| Female | 10 | 7 | 17 |
| Male | 6 | 9 | 15 |
| Pulmonary artery pressure 1 minute pre-dose(mm Hg) | Low Pulmonary Arterial Pressure | Elevated Pulmonary Arterial Pressure | Total |
|---|---|---|---|
| Mean | 30.4 ± 3.38 | 50.9 ± 10.31 | 40.7 ± 12.89 |
The record gives a start of Jul 2009, a primary completion of Dec 2009 and a completion of Dec 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2011, 1 year 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Perflutren